Keros Therapeutics (NASDAQ:KROS) vs. Climb Bio (NASDAQ:CLYM) Head-To-Head Survey

Keros Therapeutics (NASDAQ:KROS) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Keros Therapeutics and Climb Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1	4	5	0	2.40
Climb Bio	1	0	4	1	2.83

Keros Therapeutics currently has a consensus price target of $22.29, suggesting a potential upside of 24.43%. Climb Bio has a consensus price target of $9.50, suggesting a potential upside of 112.53%. Given Climb Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Climb Bio is more favorable than Keros Therapeutics.

Profitability

This table compares Keros Therapeutics and Climb Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	26.12%	9.51%	8.89%
Climb Bio	N/A	-26.43%	-25.61%

Valuation & Earnings

This table compares Keros Therapeutics and Climb Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$246.72 million	2.21	-$187.35 million	$1.54	11.63
Climb Bio	N/A	N/A	-$73.90 million	($0.76)	-5.88

Climb Bio has lower revenue, but higher earnings than Keros Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Keros Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.

Insider and Institutional Ownership

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Keros Therapeutics beats Climb Bio on 10 of the 14 factors compared between the two stocks.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.